(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
@ $8.91
发出时间: 15 Feb 2024 @ 03:26
回报率: -13.02%
上一信号: Feb 14 - 04:22
上一信号:
回报率: -1.22 %
Live Chart Being Loaded With Signals
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States...
Stats | |
---|---|
今日成交量 | 198 560 |
平均成交量 | 625 969 |
市值 | 480.00M |
EPS | $0 ( 2024-02-27 ) |
下一个收益日期 | ( $-0.440 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.87 |
ATR14 | $0.0120 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-18 | Horn Patrick Taylor | Buy | 400 000 | Stock Option (right to buy) |
2024-03-18 | Horn Patrick Taylor | Sell | 0 | No securities are beneficially owned |
2024-03-08 | Tourangeau Greg | Sell | 4 884 | Common Stock |
2024-03-04 | Sapir Alex | Buy | 43 360 | Common Stock |
2024-01-26 | Tourangeau Greg | Buy | 83 820 | Stock Option (right to buy) |
INSIDER POWER |
---|
20.73 |
Last 98 transactions |
Buy: 8 691 029 | Sell: 9 119 346 |
音量 相关性
Fulcrum Therapeutics Inc 相关性 - 货币/商品
Fulcrum Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $2.81M |
毛利润: | $633 000 (22.57 %) |
EPS: | $-1.590 |
FY | 2023 |
营收: | $2.81M |
毛利润: | $633 000 (22.57 %) |
EPS: | $-1.590 |
FY | 2022 |
营收: | $6.34M |
毛利润: | $3.93M (61.94 %) |
EPS: | $-2.35 |
FY | 2021 |
营收: | $19.16M |
毛利润: | $19.16M (100.00 %) |
EPS: | $-2.29 |
Financial Reports:
No articles found.
Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。